Repurposing of doxycycline as a novel therapeutic avenue for management of parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms without original human data
PubMed 41925933 · doi:10.1007/s10787-026-02156-y
What was done
This is a narrative review evaluating the preclinical and molecular evidence for repurposing the antibiotic doxycycline as a disease-modifying therapy for Parkinson's disease. The authors examined reported mechanisms through which doxycycline may mitigate neurodegeneration, neuroinflammation, oxidative stress, and endoplasmic reticulum stress.
What was found
The abstract reports no numerical data, statistical estimates, or study counts. It conceptually notes that doxycycline alleviates Parkinson's neuropathology in preclinical contexts, while highlighting that its precise molecular mechanisms remain incompletely understood.
Why it matters
Current Parkinson's disease management is largely symptomatic and does not halt progressive dopaminergic neurodegeneration. Identifying repurposed agents with anti-inflammatory and antioxidant properties could offer disease-modifying therapeutic strategies.
Limits
The review provides non-systematic, mechanistic reasoning without original human clinical data. No sample sizes, effect sizes, or study selection criteria are reported in the abstract. Clinical efficacy, dosing, and safety for this indication in humans remain unestablished.
Cited by
- supports Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease.